{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-095460","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.283062+00:00","generated_at":"2026-05-18T06:45:04.722843+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MiNK Therapeutics announces complete remission in testicular cancer and Phase 2 gastric cancer survival data","bullets":["Complete and durable remission in metastatic testicular cancer patient after single infusion of agenT-797 plus nivolumab, per Nature's Oncogene publication.","Phase 2 gastric cancer trial data showed immune activation, tumor infiltration, and survival beyond 12 months in checkpoint-refractory patients.","Separate case report: 42% tumor reduction and >9 months progression-free survival in gastric cancer patient with single agenT-797 infusion plus nivolumab.","Phase 2 trial (NCT06251973) actively enrolling with additional readouts expected."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-095460","json":"https://secwatch.observer/filing/0000950170-25-095460.json","markdown":"https://secwatch.observer/filing/0000950170-25-095460.md","text":"https://secwatch.observer/filing/0000950170-25-095460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000095017025095460/0000950170-25-095460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000095017025095460/inkt-20250711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T06:45:04.722843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}